Publications
Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Mol Ther 23, no. 3 (2015): 523-532.
"Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
"Comparing genome editing technologies." Genetic Engineering and Biotechnology News 34, no. 5 (2014): 1, 32-34.
"Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis." Adv Sci (Weinh) 8, no. 19 (2021).
"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models." Nature communications 12, no. 1 (2021).
"Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
"Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart." Nat Commun 12, no. 1 (2021).
"Boosting, Not Breaking: CRISPR Activators Treat Disease Models." Molecular therapy : the journal of the American Society of Gene Therapy 26, no. 2 (2018): 334-336.
"Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
"Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic acids research 45, no. 20 (2017).
"AP-1 subunits converge promiscuously at enhancers to potentiate transcription." Genome Res 31, no. 4 (2021): 538-550.
"An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles." Nature communications 10, no. 1 (2019).
"Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of the United States of America 113, no. 31 (2016): E4513-E4522.
"Advances in targeted genome editing." Current opinion in chemical biology 16, no. 3-4 (2012): 268-277.
"Addressing cell-sourcing limitations with gene therapy." IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society 22, no. 5 (2003): 65-70.
"Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert opinion on therapeutic targets 18, no. 8 (2014): 835-839.
"AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities." Current Opinion in Biomedical Engineering 29 (2024).
"AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice." Molecular therapy : the journal of the American Society of Gene Therapy 27, no. 9 (2019): 1568-1585.
"AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice." JCI insight 3, no. 23 (2018).
"Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
"Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells." In Nat Biotechnol, 1493-1501. Vol. 37. 2019.
"Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In MOLECULAR THERAPY, S93. Vol. 21. 2013.
"Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In MOLECULAR THERAPY, S126-S127. Vol. 22. 2014.
"Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
"CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In TISSUE ENGINEERING PART A, S170. Vol. 21. 2015.
"